British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

Through M&A, GSK has evolved into the pharma giant it is today, rebranding to its current name in 2022. GSK now operates in more than 75 countries and has 37 manufacturing sites. Broadly speaking ...

Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in ...

GSK) announced Tuesday that Arexvy, a Phase 3 trial for its FDA-approved vaccine against Respiratory Syncytial Virus (RSV), generated protection against the virus over three full seasons in adults ...

We will deliver our fully reinvigorated portfolio to market efficiently and maximise the considerable commercial potential, ...

GSK cuts 2024 vaccine sales forecast for second ... compared with estimates of 43.6 pence on sales of about 8 billion pounds. It kept full-year total sales and earnings forecasts unchanged.

The drug was sold at different times by GSK, Pfizer, Sanofi and Boehringer Ingelheim. Ranitidine, which was sold under the Zantac brand name, was pulled off the market in 2020 on concerns it could ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

Teva Pharmaceutical Industries Ltd. ADR-0.81% $21.06B ...